braincool.seCrawled Nov 19, 2026
BrainCool invites analysts, investors, media, and other stakeholders to a webcast on September 8 at 12:30 CET featuring CEO Anna Lindström and board member Martin Richardson.
The company aims to enhance outcomes for patients with stroke, cardiac arrest, and cancer.
BrainCool receives a **SEK 39 million+ order** from its global distributor for its **BrainCool System**, a medical device used for brain cooling in stroke and cardiac arrest patients. The deal highlights growing international demand for the company’s temperature-regulating technology. The equipment targets critical care applications where precise thermal control is essential.
BrainCool, a Lund-based company, develops medical cooling solutions for **Targeted Temperature Management**. The firm operates in two key areas: **brain cooling for intensive care** and **cooling therapies for oncology (cancer care)**. The company’s CEO discusses recent expansion and plans for capital issuance to support further growth.
BrainCool’s new CEO, Berg, highlights the company’s growth phase and expresses confidence in the global market potential for its cooling devices. The company targets expanding demand for its specialized technology, positioning itself for broader adoption.
BrainCool secures financing to expand production capacity for its medical cooling devices. The company’s **BrainCool System** (IQool in the US) targets stroke and cardiac arrest patients, while its pipeline includes **Cooral System** and **RhinoChill**. The funding supports scaling manufacturing to meet growing demand for rapid hyperthermia treatments.
BrainCool AB develops a cooling system for brain surgery to reduce patient risks. The company’s technology aims to lower brain temperature during procedures, potentially improving outcomes. This analysis covers BrainCool’s innovation, market positioning, and operational status as of mid-2016.